Early luteal function following danazol therapy for endometriosis
article
OA: closed
CC0
AI-generated summary
This study found that danazol therapy for endometriosis did not impair early luteal function, as evidenced by normal progesterone levels and endometrial development in women after treatment.
One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works
Abstract
The luteal phase of 20 infertile women with endometriosis who were treated with danazol (600 mg daily for 6 months) was studied by basal body temperature, plasma progesterone (P), oestradiol (E2) and prolactin (PRL) determination, and endometrial biopsy, in any one of the first three cycles after discontinuation of danazol. All endometrial specimens were noted to be fundal samples and were clearly progestational after danazol therapy. Abnormal secretory phases were detected in three patients, as in the pre-danazol control cycles. Moreover, plasma levels of P, E2 and PRL in post-danazol cycles were similar to those found in control cycles and fell within the normal range in all cases except for one patient having hyperprolactinaemia. In conclusion, our study shows that endometrial inadequacy is not the cause of the increased fetal wastage previously reported among proximally conceived pregnancies after danazol therapy for endometriosis.
My notes (saved in your browser only)
Condition tags
MeSH descriptors
Citation neighborhood (no data yet)
We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.
Source provenance
- europepmc
- last seen: 2026-06-11T06:19:48.454388+00:00
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- pubmed
- last seen: 2026-05-13T22:09:35.489789+00:00
- unpaywall
- last seen: 2026-06-02T02:00:03.124865+00:00
License: CC0
· commercial use OK